trending Market Intelligence /marketintelligence/en/news-insights/trending/zgctqt-ab7seivg1smge0a2 content esgSubNav
In This List

TaiMed bags US FDA approval for HIV drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TaiMed bags US FDA approval for HIV drug

The U.S. Food and Drug Administration approved TaiMed Biologics Inc.'s Trogarzo to treat certain adults with HIV.

The regulator granted the approval for the drug to TaiMed Biologics USA Corp. for the treatment of adult patients with HIV-1 who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered into a vein once every 14 days by a trained medical professional and used in combination with other antiretroviral medications. The drug attaches to the CD4+ protein molecules on host cells and blocks the HIV virus from infecting the cells.

Antiretroviral drugs are medications that do not kill or cure the HIV virus but can slow down or prevent its growth.

The safety and efficacy of the drug were tested in a study that involved 40 heavily pretreated patients with multidrug-resistant HIV-1 infection who continued to have high levels of virus in their blood despite antiretroviral therapy. In the trial, 43% of patients experienced suppressed levels of the HIV virus in the body.

Viral suppression is reached when the level of HIV in the blood is very low and undetectable, though it does not mean a person is cured as HIV still remains in the body.

TaiMed's partner Theratechnologies Inc. owns commercialization rights for the drug in the U.S., Canada, EU, Israel, Norway, Russia and Switzerland.